Welcome to the international HTA database

Showing [22278 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2022	National Institute for Health and Care Excellence (NICE)	Teduglutide for treating short bowel syndrome. NICE technology appraisal guidance 804
2022	NIHR Health Technology Assessment programme	Shock-absorbing flooring for fall-related injury prevention in older adults and staff in hospitals and care homes: the SAFEST systematic review
2022	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Conductive intravesical chemohyperthermia with mitomycin in non-muscle invasive bladder cancer: review of guidelines and ongoing research]
2022	National Institute for Health and Care Excellence (NICE)	Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides. NICE technology appraisal guidance 805
2022	NIHR Health Technology Assessment programme	Endovascular stent grafting and open surgical replacement for chronic thoracic aortic aneurysms: a systematic review and prospective cohort study
2022	National Institute for Health and Care Excellence (NICE)	Belimumab for treating lupus nephritis (terminated appraisal). NICE technology appraisal guidance 806
2022	Scottish Health Technologies Group (SHTG)	Closed loop systems and the artificial pancreas for type I diabetes mellitus (T1DM)
2022	Austrian Institute for Health Technology Assessment (AIHTA)	Perinatal and infant mental health care models and pathways
2022	WorkSafeBC	Environmental exposure to respirable particles and estimated risk of sarcoidosis
2022	National Institute for Health and Care Excellence (NICE)	Roxadustat for treating symptomatic anaemia in chronic kidney disease. NICE technology appraisal guidance 807
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: next-generation sequencing (NGS) panels for muscle disease]
2022	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Assessment and clinical management of self-harm in adolescence: evidence-based protocol]
2022	WorkSafeBC	Tinnitus and the COVID-19 vaccine
2022	Agency for Healthcare Research and Quality (AHRQ)	Acute treatments for episodic migraine
2022	National Institute for Health and Care Excellence (NICE)	Fenfluramine for treating seizures associated with Dravet syndrome. NICE technology appraisal guidance 808
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis by NAAT]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Delamanid (repeal of the exemption: pulmonary multi-drug resistant tuberculosis, ≥ 10 kg)]
2022	Malaysian Health Technology Assessment (MaHTAS)	Early cancer detection test for lung (EarlyCDT-Lung)
2022	WorkSafeBC	Vision therapy as treatment for traumatic brain injury: 2022 update
2022	National Institute for Health and Care Excellence (NICE)	Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease. NICE technology appraisal guidance 809
2022	Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS)	[The use of social media and electronic communication in the delivery of youth protection services to young people in difficulty and their families]
2022	NIHR Health Services and Delivery Research programme	Safety of disinvestment in mid- to late-term follow-up post primary hip and knee replacement: the UK SAFE evidence synthesis and recommendations
2022	Health Technology Wales (HTW)	Laryngeal biopsies in the outpatient setting in people with suspected head and neck dysplasia/cancer
2022	WorkSafeBC	Inpatient versus outpatient programs as treatment for PTSD
2022	National Institute for Health and Care Excellence (NICE)	Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence. NICE technology appraisal guidance 810
2022	NIHR Health Technology Assessment programme	Biomarkers for assessing acute kidney injury for people who are being considered for admission to critical care: a systematic review and cost-effectiveness analysis
2022	WorkSafeBC	Oral collagen supplements for shoulder sprain strain
2022	Agency for Healthcare Research and Quality (AHRQ)	Antibody response following SARS-CoV-2 infection and implications for immunity: a living rapid review
2022	National Institute for Health and Care Excellence (NICE)	Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal). NICE technology appraisal guidance 811
2022	NIHR Health Technology Assessment programme	REVascularisation of Ischaemic VEntricular Dysfunction (REVIVED): a randomised comparison of percutaneous coronary intervention (with optimal medical therapy) vs. optimal medical therapy alone for heart failure secondary to coronary disease
2022	Gesundheit Osterreich GmbH (GOeG)	[Cost effectiveness of communication training for health care professionals]
2022	WorkSafeBC	Convergence insufficiency and COVID-19 infection
2022	National Institute for Health and Care Excellence (NICE)	Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 812
2022	NIHR Health Technology Assessment programme	Improving the prediction of metastatic disease in primary colorectal cancer: Prospective multicentre evaluation of a prognostic model of conventional predictive variables and novel variables derived from perfusion computed tomography (Perfusion CT)
2022	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Bronchial thermoplasty in severe asthma]
2022	Malaysian Health Technology Assessment (MaHTAS)	First line targeted therapy for advanced hepatocellular carcinoma (aHCC)
2022	WorkSafeBC	Lose-dose naltrexone as treatment for post-COVID conditions
2022	National Institute for Health and Care Excellence (NICE)	Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors. NICE technology appraisal guidance 813
2022	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Radiofrequency ablation for treatment of symptomatic uterine myomas]
2022	Scottish Health Technologies Group (SHTG)	vCreate Neuro for the diagnosis and treatment of adults and children with epilepsy and other neurological disorders
2022	National Institute for Health and Care Excellence (NICE)	Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis. NICE technology appraisal guidance 814
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Magnetic sphincter augmentation for gastrooesophageal reflux disease (Addendum to Commission E21-06)]
2022	National Institute for Health and Care Excellence (NICE)	Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 815
2022	NIHR Health Technology Assessment programme	Enhancing social-emotional health and wellbeing in the early years: a community-based randomised controlled trial (and economic) evaluation of the Incredible Years Infant and Toddler (0-2) Parenting Programmes
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Magnetic sphincter augmentation for gastrooesophageal reflux disease]
2022	National Institute for Health and Care Excellence (NICE)	Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer. NICE technology appraisal guidance 816
2022	NIHR Health Technology Assessment programme	Development and evaluation of machine learning methods in whole body magnetic resonance imaging with diffusion weighted imaging for staging of patients with cancer (MAchine Learning In whole Body Oncology, MALIBO)
2022	NIHR Health Technology Assessment programme	Endometrial scratch to increase live birth rates in women undergoing first-time in vitro fertilisation: RCT and systematic review
2022	Agency for Care Effectiveness (ACE)	Revivent TC transcatheter ventricular enhancement system for ischemic heart failure
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Polatuzumab Vedotin (new therapeutic indication: diffuse large B-cell lymphoma (DLBCL), combination with rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP))]
2022	National Institute for Health and Care Excellence (NICE)	Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence. NICE technology appraisal guidance 817
2022	NIHR Health Technology Assessment programme	FEMME trial: Randomised trial of treating Fibroids with either Embolisation or MyoMectomy to measure the Effect on quality of life
2022	Agency for Care Effectiveness (ACE)	Vagus nerve stimulation with the VITARIA System for heart failure with reduced ejection fraction
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Tisagenlecleucel (new therapeutic indication: follicular lymphoma, pretreated patients)]
2022	National Institute for Health and Care Excellence (NICE)	Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma. NICE technology appraisal guidance 818
2022	Agency for Care Effectiveness (ACE)	Caption guidance to guide image acquisition in point-of-care echocardiography for patients with cardiovascular disease
2022	National Institute for Health and Care Excellence (NICE)	Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies. NICE technology appraisal guidance 819
2022	NIHR Health Technology Assessment programme	A randomised, multi-stage phase II/III study of standard first-line therapy (sunitinib or pazopanib) comparing temporary cessation with allowing continuation, in the treatment of locally advanced and/or metastatic renal cancer (the STAR trial)
2022	Agency for Care Effectiveness (ACE)	The PrecivityAD test for the prognosis of Alzheimer's disease
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Voxelotor (haemolytic anaemia in sickle cell disease, monotherapy or combination with hydroxycarbamide, ≥ 12 years)]
2022	National Institute for Health and Care Excellence (NICE)	Brolucizumab for treating diabetic macular oedema. NICE technology appraisal guidance 820
2022	NIHR Health Technology Assessment programme	Fast-Forward: a randomised clinical trial testing a 1-week course of curative whole breast radiotherapy against a standard 3-week schedule in terms of local cancer control and late adverse effects in women with early breast cancer
2022	Basque Office for Health Technology Assessment (OSTEBA)	[Autism spectrum disorder: scientific evidence on its detection, diagnosis and treatment]
2022	Agency for Care Effectiveness (ACE)	Artificial intelligence and its clinical applications
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Avapritinib (new therapeutic indication: systemic mastocytosis, after at least 1 prior therapy)]
2022	National Institute for Health and Care Excellence (NICE)	Avalglucosidase alfa for treating Pompe disease. NICE technology appraisal guidance 821
2022	Basque Office for Health Technology Assessment (OSTEBA)	[Image-guided spinal fusion technology]
2022	Agency for Care Effectiveness (ACE)	3D printing and its clinical applications
2022	National Institute for Health and Care Excellence (NICE)	Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal). NICE technology appraisal guidance 822
2022	Basque Office for Health Technology Assessment (OSTEBA)	[Temporary percutaneous circulatory support devices for the treatment and prevention of cardiogenic shock: analysis of efficacy, effectiveness and safety]
2022	Agency for Care Effectiveness (ACE)	Overview of clinical applications of telemedicine
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Tebentafusp (uveal melanoma, HLA-A*02:01-positive)]
2022	National Institute for Health and Care Excellence (NICE)	Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer. NICE technology appraisal guidance 823
2022	Agency for Care Effectiveness (ACE)	Bilateral cochlear implants for children with severe-to-profound sensorineural hearing loss in both ears
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Glucarpidase (reduction of toxic plasma methotrexate concentrations; aged 28 days and older)]
2022	National Institute for Health and Care Excellence (NICE)	Dexamethasone intravitreal implant for treating diabetic macular oedema. NICE technology appraisal guidance 824
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Idebenone (reassessment after the deadline: Leber's Hereditary Optic Neuropathy)]
2022	Agency for Healthcare Research and Quality (AHRQ)	Diagnostic errors in the emergency department: a systematic review
2022	National Institute for Health and Care Excellence (NICE)	Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis. NICE technology appraisal guidance 825
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: amyotrophic lateral sclerosis with or without frontotemporal dementia NGS panel]
2022	Scottish Health Technologies Group (SHTG)	The Psychology Adding Value – Epilepsy Screening (PAVES) and early intervention for children and young people with epilepsy at risk of mental health problems
2022	Center for Drug Evaluation (CDE)	Patient involvement in the health technology assessment process in Taiwan
2022	National Institute for Health and Care Excellence (NICE)	Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal). NICE technology appraisal guidance 826
2022	NIHR Health Technology Assessment programme	Gastric Bypass, adjustable gastric Banding or Sleeve gastrectomy surgery to treat severe and complex obesity: a multi-centre randomised controlled trial (The By-Band-Sleeve Study)
2022	NIHR Health Technology Assessment programme	POSNOC - POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: A randomised controlled trial of axillary treatment in women with early stage breast cancer who have metastases in one or two sentinel nodes
2022	Agency for Care Effectiveness (ACE)	Percutaneous vertebral augmentation systems for treating patients with vertebral compression fractures
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Voretigene Neparvovec (reassessment after the deadline: inherited retinal dystrophy)]
2022	Scottish Health Technologies Group (SHTG)	A national radiology information system (RIS) for Scotland: perceived benefits and constraints to implementation
2022	National Institute for Health and Care Excellence (NICE)	Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy. NICE technology appraisal guidance 827
2022	NIHR Health Technology Assessment programme	The PRmotion Of Physical activity through structured Education with differing Levels of ongoing Support for those with prediabetes (PROPELS): randomised controlled trial in a diverse multi-ethnic community
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Somatrogon (growth disturbance due to growth hormone deficiency, ≥ 3 to < 18 years]
2022	National Institute for Health and Care Excellence (NICE)	Ozanimod for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 828
2022	NIHR Health Technology Assessment programme	E-FREEZE: a randomised controlled trial evaluating the clinical and cost-effectiveness of a policy of freezing all embryos followed by thawed frozen embryo transfer, compared with a policy of fresh embryo transfer in women undergoing in-vitro fertilization
2022	Agency for Care Effectiveness (ACE)	Continuous subcutaneous insulin infusion therapy for treating type 1 diabetes
2022	National Institute for Health and Care Excellence (NICE)	Upadacitinib for treating active ankylosing spondylitis. NICE technology appraisal guidance 829
2022	NIHR Health Technology Assessment programme	Treatment of Advanced Glaucoma Study (TAGS): a multicentre randomised controlled trial comparing primary medical treatment with primary trabeculectomy for people with newly diagnosed advanced glaucoma
2022	NIHR Health Technology Assessment programme	RCT of clinical and cost-effectiveness of drug coated balloons, drug eluting stents and balloon angioplasty with bail-out bare metal stent revascularisation strategies for severe limb ischaemia due to femoro-popliteal disease: BASIL-3 (Balloon vs Stenting in Severe Ischaemia of the Leg)
2022	National Institute for Health and Care Excellence (NICE)	Pembrolizumab for adjuvant treatment of renal cell carcinoma. NICE technology appraisal guidance 830
2022	National Institute for Health and Care Excellence (NICE)	Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids. NICE technology appraisal guidance 832
2022	NIHR Health Technology Assessment programme	Accuracy and cost-effectiveness of dynamic contrast enhanced computed tomography in the characterisation of solitary pulmonary nodules